Cost-effectiveness Analyses on Four Intervening Regiments for Hypertension in Workplace

邓彩云,汪远征,刘星,梁洁,金成,吴寿岭

DOI: https://doi.org/10.16439/j.cnki.1673-7245.2013.02.015

2013-01-01

Abstract:Objective To analysis the cost-effectiveness of four drug combinations for hypertension intervention in workplace. Methods From April 2009 to May 2010,a total of 4023 [4023male,67 female, age (45.5±6.5) ]primary hypertensive active staff who worked in underground and underground ancillary units of Kailuan Group limited liability company received comprehensive interventions. Interventions consisted of free distribution of antihypertensive drugs, communication and education, and administrative intervention. Antihypertensive drugs included the following combinations: ①Group 1 (n=1115): nitrendipine 5 mg/bid plus captopril 12.5 mg/bid; ②Group 2 (n=704): the nitrendipine 5 mg/bid plus spironolactone 20 mg/d; ③Group 3 (n=794): hydrochlorothiazide 12.5 mg/d plus captopril 12.5 mg/bid; ④Group 4 (n=1477): the hydrogen hydrochlorothiazide 12.5 mg/d plus spironolactone 20 mg/d. During the intervention, the blood pressure was measured every two weeks. All the subjects were followed-up for one year on average. The curative effects were observed before and after the intervention, and the cost-effectiveness analyses were conducted by the principles of pharmacoeconomics. Results There were significant differences in cost-effectiveness between groups receiving different drug combination interventions after one year. The total effective rate of Group 2 (61.51%) was the lowest, while that of the Group 4 (80.37%) was the highest. There was no statistic difference in the total effective rates between Group 1 and Group 3 (χ 2=0.074, P0.05). The intervention cost of Group 3 was the lowest, and that of the Group 4 was moderate. Cost-effectiveness showed that, compared with that of the Group 3, the annual intervention cost of Group 4 (hydrochlorothiazide plus spironolactone) increased 1.72 yuan for every one percentage increase in its hypotensive effect; the annual intervention cost of Group 4 increase 7.25 yuan for every 1 mm Hg decrease in systolic blood pressure (SBP) and 10.17 yuan for every 1 mm Hg decrease in diastolic blood pressure (DBP). The cost of Group 1 and Group 2 were higher than that of Group 3 without better hypotensive effects. Conclusions According to the comprehensive analysis of economics and pharmacotherapeutics, Group 4 (hydrochlorothiazide plus spironolactone) shows the best results of cost-effectiveness among the four antihypertensive drug combination interventions in the workplace.